EFTA01113739Set 9
37p2,922w
registered in ALK+ NSCLC pts (3-5%
NSCLC pts)
OSE
EFTA01113747
OSE 2101:Phase Ill Protocol & Objectives
HLA A2 NSCLC population, open, randomized, multi-center
comparative study: 500pts
■ Versus reference
https://www.justice.gov/epstein/files/DataSet%209/EFTA01113739.pdf